Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Stay at the forefront of gynecologic oncology with The Lancet, featuring groundbreaking research and authoritative reviews on ovarian, endometrial, and cervical cancers that help inform the latest advances in diagnosis, treatment, and patient care.
Investigators reported positive final overall survival findings for relacorilant plus nab-paclitaxel, with further study needed to determine sequencing with other agents.
The Lancet Group reaches millions of clinicians and researchers worldwide.
In ENGOT-ov65/KEYNOTE-B96, investigators reported improved PFS and OS with pembrolizumab added to weekly paclitaxel (± bevacizumab); safety was consistent with known profiles.
Investigators reported positive final overall survival findings for relacorilant plus nab-paclitaxel, with further study needed to determine sequencing with other agents.
In a primary care clinic setting, the authors report higher screening coverage with a universal offer of HPV self-testing than with clinician-taken cervical sampling; the study design is not stated in the available Research in Context text.
In the LARA trial, findings support further randomised evaluation of this immune checkpoint inhibitor–angiogenesis inhibitor combination in Asian women with recurrent disease.
A worldwide secondary analysis from the VENUSCANCER project describes population-based indicators of initial treatment consistency with major international guidelines across 39 countries.
In this long-term randomised trial analysis, investigators reported improved overall and recurrence-free survival with adjuvant chemoradiotherapy versus radiotherapy alone, with the greatest absolute benefit in p53-abnormal cancers and no apparent added value in MMRd or POLE-mutated cancers.
In this open-label, randomised phase 3 trial, the primary patient-reported outcome did not reach statistical significance, though MIRV did not seem to impair health-related quality of life versus chemotherapy.
In COMPASSION-16, a phase 3 trial in metastatic, persistent, or recurrent cervical cancer, investigators reported that adding cadonilimab to platinum-based chemotherapy with or without bevacizumab improved progression-free and overall survival.
In INTERLACE, a randomised phase 3 study, 6 weeks of carboplatin and paclitaxel immediately before standard chemoradiotherapy was associated with improved progression-free and overall survival in women with locally advanced cervical cancer.
At the second protocol-specified interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, investigators reported an overall survival benefit with pembrolizumab given with and after chemoradiotherapy versus chemoradiotherapy alone.